# START-001 (NCT05592626)

> A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05592626
- Phase: PHASE1, PHASE2
- Status: RECRUITING
- Sponsor: Marengo Therapeutics, Inc.
- Conditions: Advanced Solid Tumors; Genital Neoplasm, Female; Urogenital Neoplasms; Lung Neoplasm; Neoplasms by Site; Papillomavirus Infection; Epstein-Barr Virus Infections; Carcinoma; Neoplasms; Vulvar Neoplasms; Vulvar Diseases; Abdominal Neoplasm; NSCLC (Non-small Cell Lung Cancer); Colorectal Cancer
- Interventions: STAR0602; Irinotecan (Camptosar); Docetaxel (Taxotere)
- Enrollment: 366
- Primary outcome: Phase 1 (Dose Escalation):Number of Participants with Dose-limiting Toxicities (DLTs) in Cycle 1
- Primary outcome: Phase 1 and 2 (Dose Escalation and Expansion): Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)
- Primary outcome: Phase 2 (Dose Expansion): Percentage of Participants with Overall Objective Tumor Responses (ORR)

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- YouTube: 1
- X threads: 1
- Bluesky threads: 1

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=start-001-nct05592626